Physician profile
Ronald Lee Hopping
NPI 1649324542
$2,306.94
in general payments reported to CMS, 2019-2025
14 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $138 · 2021: $94.74 · 2022: $295 · 2023: $148 · 2024: $365 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Entertainment: $351 · Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Entertainment | $350.75 |
| Food and Beverage | $293.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $862.57 | 2019-2024 | Tearcare System |
| Optos, INC. | $572.12 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $192.31 | 2019-2025 | Dailies Total1, Precision7 |
| Bausch & Lomb Americas INC. | $160.85 | 2022-2024 | Miebo |
| Abb Con-Cise Optical Group LLC | $94.74 | 2021 | |
| Abbvie INC. | $82.78 | 2022 | |
| Glaukos Corporation | $81.41 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Maculogix, INC. | $73.61 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.20 | 2019 | |
| Biotissue Holdings INC. | $38.55 | 2019-2024 | |
| Coopervision INC. | $30.73 | 2022 | |
| Carl Zeiss Meditec, INC. | $27.24 | 2020 | |
| Oyster Point Pharma, INC. | $21.27 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $19.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hopping listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.